证券时报·数据宝统计显示，10月30日有32家香港上市公司进行了股份回购，合计回购3465.59万股，回 购金额1.55亿港元。 | 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | 港元） | （港元） | （港元） | （万港元） | | 06186 | 中国飞鹤 | 1200.00 | 5022.69 | 4.200 | 4.170 | 12892.59 | | 00386 | 中国石油化 | 477.60 | 1972.30 | 4.220 | 4.100 | 79358.34 | | | 工股份 | | | | | | | 02005 | 石四药集团 | 500.00 | 1541.46 | 3.130 | 3.030 | 14811.59 | | 02598 | 连连数字 | 138.35 | 1131.18 | 8.340 | 7.850 | 4041.24 | | 02273 | 固生堂 | 29.01 | 832.54 | ...

Core Insights - A total of 30 companies conducted share buybacks on October 30, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2] - The total buyback amount for China Feihe was 50.23 million yuan, with 12 million shares repurchased, representing a significant investment in its own stock [1][2] Summary by Company - **China Feihe (06186)**: Repurchased 12 million shares for 50.23 million yuan; cumulative buybacks for the year reached 30.95 million shares, accounting for 0.341% of total share capital [2] - **China Petroleum & Chemical Corporation (00386)**: Repurchased 4.78 million shares for 19.72 million yuan; cumulative buybacks for the year reached 102 million shares, accounting for 0.080% of total share capital [2] - **Stone Four Pharmaceutical Group (02005)**: Repurchased 5 million shares for 15.41 million yuan; cumulative buybacks for the year reached 44.20 million shares, accounting for 1.498% of total share capital [2] - **Lianlian Digital (02598)**: Repurchased 1.38 million shares for 11.31 million yuan; cumulative buybacks for the year reached 4.45 million shares, accounting for 1.065% of total share capital [2] - **Gushengtang (02273)**: Repurchased 290,100 shares for 8.33 million yuan; cumulative buybacks for the year reached 5.88 million shares, accounting for 2.482% of total share capital [2] - **Lianyi Technology-W (09959)**: Repurchased 2.3 million shares for 7.42 million yuan; cumulative buybacks for the year reached 80.04 million shares, accounting for 3.746% of total share capital [2] - **Mongolian Dairy (02319)**: Repurchased 400,000 shares for 5.70 million yuan; cumulative buybacks for the year reached 22.42 million shares, accounting for 0.573% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: Repurchased 280,000 shares for 4.21 million yuan; cumulative buybacks for the year reached 7.84 million shares, accounting for 9.216% of total share capital [2] - **Other Companies**: Various other companies also participated in buybacks, with amounts ranging from 4.51 million yuan to 6 million yuan, and share counts varying significantly [2]

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 石四药集团 | 曲继广 | 好仓 | 12.17 亿股 | 12.22 亿股 | 41.39%(最新) | | (02005) | | | | | 41.22%(前次) | 智通财经APP获悉，石四药集团(02005)于2025年10月31日进行了最新股东权益披露。 ...

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.10.30 | 500.00 | 3.130 | 3.030 | 1541.46 | | 2025.10.21 | 210.00 | 2.920 | 2.880 | 608.13 | | 2025.10.14 | 210.00 | 2.940 | 2.870 | 609.08 | | 2025.10.10 | 150.00 | 2.970 | 2.940 | 442.95 | | 2025.10.08 | 200.00 | 2.880 | 2.850 | 572.66 | | 2025.10.06 | 300.00 | 2.930 | 2.880 | 869.89 | | 2025.09.23 | 500.00 | 2.960 | 2.920 | 1467.48 | | 2025.09.12 | 90.00 | 3.060 | 3.050 | 275.11 | | 2025.09.11 | 600.00 | 3.040 | 2 ...

格隆汇10月30日丨石四药集团(02005.HK)发布公告，2025年10月30日耗资1541.5万港元回购500万股， 回购价格每股3.03-3.13港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months ending September 30, 2025, was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]

石四药集团(02005)发布截至2025年9月30日止9个月业绩，以港元而言，集团截至2025年9月30日止9个 月的未经审核营业额约31.02亿港元，同比减少31.6%(集团截至2025年6月30日止6个月的收益:同比减少 35.7%)，主要由于静脉输液的销量及安瓿注射液的未经审核营业额下降。各种形式的带量采购(包括国 家集采及地方联盟集采)范围扩大以及国内外行业竞争加剧带来持续的价格压力。集团截至2025年9月30 日止9个月的未经审核毛利约12.94亿港元，同比减少46.1%，其未经审核毛利率约为41.7%，同比减少 11.3百分点。截至2025年9月30日止9个月，集团的未经审核公司股东应占溢利约3.99亿港元，同比减少 56.6%(2025年上半年的股东应占溢利:同比减少58.7%)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：2005） 截至二零二五年九月三十日止九個月 未經審核經營業績 本公告乃石四藥集團有限公司（「本公司」）根據證券及期貨條例（香港法例第571章）第 XIVA部之內幕消息條文（定義見香港聯合交易所有限公司證券上市規則（「上市規則」）） 及上市規則第13.09(2)條而作出。 本公司董事局（「董事局」）根據本公司及其附屬公司（統稱「本集團」）未經本公司核數師 審核或審閱之管理賬目，欣然公告以下本集團截至二零二五年九月三十日止九個月之未 經審核經營業績。 本集團銷售主要在中國進行並以人民幣計值，截至二零二五年九月三十日止九個月，人民幣 兌港元（「港元」）較去年同期貶值約0.9%。以港元而言，本集團截至二零二五年九月三十 日止九個月之未經審核營業額約31.02億港元，同比減少31.6%（本集團截至二零二五年六月 三十日止六個月（「二零二五年上半年」）之收益: 同比減 ...

Core Viewpoint - The company, 石四药集团, announced its intention to bid for 12 products across 14 specifications in the 11th national centralized drug procurement in China scheduled for October 27, 2025 [1] Product Summary - The products intended for bidding include: - 二羟丙茶硷注射液 (2ml:0.3g) - 富马酸福莫特罗吸入溶液 (2ml:20g) - 马来酸氟伏沙明片 (100mg and 50mg) - 注射用氯诺昔康 (8mg) - 盐酸肾上腺素注射液 (1ml:1mg) - 盐酸溴己新注射液 (2ml:4mg) - 复方电解质注射液 (500ml) - 复方电解质注射液 (II) (500ml and 1000ml) - 尼可地尔片 (5mg) - 硫酸沙丁胺醇注射液 (1ml:0.5mg) - 盐酸贝尼地平片 (8mg) - 碳酸氢钠注射液 (50ml:4.2g) [1]